Poster Abstracts • OFID 2018:5 (Suppl 1) • S437 soon after collection for batch assay Methods. "Real-world" studies documenting high interpatient variability in PIP/TZB pharmacokinetics in the critically ill should account for pre-analytical variation due to sample degradation with clear sample handling protocols.
Background. Current dogma suggests optimizing AG doses based on peak concentration (C max ), without consideration of daily drug exposure (AUC 24 ). The correlation between attainment of the TOB pharmacokinetic-pharmacodynamic (PK-PD) targets, C max :MIC and AUC 24 :MIC ratio was explored using a TOB population PK (PPK) model, Monte Carlo simulation, and PA nonclinical PK-PD data.
Methods. Simulated TOB plasma concentration-time profiles for traditional (TD) and extended interval (EID) dosing regimens were generated using a published PPK model [Aarons. Br J Clin Pharmacol 1989; 28:305-14] . Simulations were performed by bootstrapping from a database of >1,400 infected patients enrolled in clinical trials to achieve n = 1,000 per renal function group defined by varying creatinine clearance ranges. Variability in average TOB AUC 24 and C min over 48 hours was assessed to determine dosing regimens that produced, for each renal group, (1) ≤50% difference in median AUC 24 compared with that of normal renal function (90-120 mL/minute); (2) ≤25% of simulated AUC 24 values beyond the fifth and 95 th percentiles of the AUC 24 distribution for normal renal function; and (3) ≤20% of C min values >2 mg/L. Once these requirements were met across renal groups, the percentages of simulated patients achieving the C max :MIC target ≥10 and AUC 24 :MIC target for 1-log 10 CFU reduction (≥83.9) at MIC values of 0.5-2 mg/L were assessed.
Results. Distributions of simulated TOB AUC 24 and C min values by renal group are shown in Figure 1 . Figures 2 and 3 depict the discordance between C max :MIC and AUC 24 :MIC target attainment for TD and EID, respectively. Of 6,000 simulated patients receiving TD, 20.0% achieved the AUC 24 :MIC target at an MIC = 1 mg/L without producing a C max :MIC ≥10, whereas 55.1% of 5,000 simulated patients receiving EID failed to achieve the AUC 24 :MIC target despite producing a C max :MIC ≥10.
Conclusion. At clinically relevant MICs, AG TD regimens optimized based on C max may result in patients receiving higher than necessary doses, while EID regimens may lead to underdosing. Given the transient nature of a peak concentration compared with overall drug exposure, the adequacy of AG dosing should consider variability in drug clearance (AUC 24 ) over variability in distributional volume (C max ). Background. AMK exhibits concentration-dependent bactericidal activity where larger intermittent doses with higher peaks (C max ) may be less toxic than more frequent dosing while achieving similar efficacy. An AMK containing regimen was used for treatment of M. abscessus odontogenic outbreak infections in children. Additionally, synergy has been observed between AMK and clofazimine (CFZ). Previous reports of daily AMK for M. abscessus infection in children resulted in high rates of toxicity. This is the first report of PK and safety of AMK dosed TIW for disseminated M. abscessus infections in children.
Disclosures
Methods. Treatment regimen initially included high dose AMK TIW with azithromycin (AZM) and a β-lactam followed by lower dose AMK with CFZ and AZM. Data collected included demographics, weekly laboratories, treatment details and adverse effects. AMK levels were drawn at 2-and 6-hour postdose for PK determination and to attain a C max of 8 × minimum inhibitory concentration. Audiograms were obtained every 2 weeks.
Results. Of 27 children who received treatment, 13 were male, mean age was 5.8 years (3.0-9.4 years) and mean weight was 21.4 kg (14-37 kg). Dissemination (lung nodules (16 [59.3%] ) and granulomatous cervical lymphadenitis (10 [37%]) was common. All patients underwent oral surgical debridement. Mean total treatment duration was 135 ± 19 days (mean ± SD). Initial AMK dose was 23.7 ± 5 mg/kg to achieve a C max 58.7 ± 6.3 mg/L. Dosage was reduced to 12.6 ± 2.2 mg/kg after addition of CFZ at 65 ± 14 days to target C max 25 ± 5 mg/L. No nephrotoxicity was noted, however a transient increase in serum creatinine of 50% from baseline was seen in seven (25%) patients. Two children experienced mild-moderate hearing loss during treatment which normalized by final audiogram. All children showed evidence of jaw healing with resolved or improving lung nodules at 12-months follow-up.
Conclusion. TIW AMK containing regimen is well tolerated and potentially less toxic than daily dosing for treatment of M. abscessus infection in children. 
